

Evaluation Report for Category B, Subcategory 1.1 Application

Application Number: 2020-2111
Application: Changes to TGAI Product Chemistry – New Source (site) Same Registrant
Product: ADAMA TEBUCONAZOLE TECHNICAL
Registration Number: 33447
Active ingredient (a.i.): Tebuconazole
PMRA Document Number: 3385171

Purpose of Application

The purpose of this submission is to add new manufacturing sites to ADAMA TEBUCONAZOLE TECHNICAL.

Chemistry Assessment

Common Name: Tebuconazole
IUPAC* Chemical Name: (RS)-1-(4-chlorophenyl)-4,4-dimethyl-3-(1H-1,2,4-triazol-1-ylmethyl)pentan-3-ol
CAS† Chemical Name: α -[2-(4-chlorophenyl)ethyl]- α -(1,1-dimethylethyl)-1H-1,2,4-triazole-1-ethanol

* International Union of Pure and Applied Chemistry

† Chemical Abstracts Service

ADAMA TEBUCONAZOLE TECHNICAL has the following properties:

Property	Result
Colour and physical state	White solid
Nominal concentration	98.3%
Odour	Characteristic
Density	0.521 g/cm ³ at 19.5°C
Vapour pressure	3.44 × 10 ⁻⁵ Pa at 40.3°C 1.44 × 10 ⁻⁵ Pa at 33.6°C 1.9 × 10 ⁻⁶ Pa at 20°C (extrapolation)
pH	8.54 (1% w/v aqueous solution)

Property	Result
Solubility in water	38.1 mg/L (20°C)
n-Octanol/water partition coefficient	log K _{ow} = 3.5

The required chemistry data for ADAMA TEBUCONAZOLE TECHNICAL have been provided, reviewed, and found to be acceptable.

Health, Environmental and Value Assessments

Health, environmental and value assessments were not required for this application.

Conclusion

The Pest Management Regulatory Agency has completed an assessment of the information provided, and has found the information sufficient to support addition of the manufacturing sites to ADAMA TEBUCONAZOLE TECHNICAL.

References

PMRA Document Number	References
2738949	2015, Determination of the Thermal and Air Stability of and Corrosion Characteristics MIL S 190/12-Tebuconazole TGAI, DACO: 2.14.13 CBI
2738950	2015, Physical State, Appearance, Color and Odor of MIL S 190/12-Tebuconazole TGAI, DACO: 2.14.1,2.14.2,2.14.3 CBI
2738951	2004, Boiling Temperature of HT 308 Technical-Tebuconazole TGAI, DACO: 2.14.5
2738952	2004, Melting Temperature of HT 308 Technical-Tebuconazole TGAI, DACO: 2.14.4
2738953	2015, Determination of the Bulk Density of MIL S 190/12-Tebuconazole TGAI, DACO: 2.14.6 CBI
2738954	1999, General GT 308 Technical physico-chemical data, DACO: 2.14.10,2.14.11,2.14.12,2.14.7,2.14.8,2.14.9 CBI
3126212	2016, Manufacturing Process and Formation of Impurities of Tebuconazole Technical – [PRIVACY INFO REMOVED], DACO: 2.11.1,2.11.2,2.11.3,2.11.4 CBI
3126213	2017, Manufacturing Process of Tebuconazole Technical Grade Active Ingredient-[PRIVACY INFO REMOVED], DACO: 2.11.1,2.11.2,2.11.3,2.11.4 CBI
3126215	2014, Formation of Impurities Tebuconazole TC-[PRIVACY INFO REMOVED], DACO: 2.11.4 CBI
3126217	2017, Validation of Analytical Methods for Tebuconazole and Associated Impurities-[PRIVACY INFO REMOVED], DACO: 2.13.1,2.13.2 CBI
3126219	2017, Validation of Analytical Methods for Tebuconazole and Associated Impurities-[PRIVACY INFO REMOVED], DACO: 2.13.1,2.13.2,2.13.3,2.13.4 CBI
3126221	2016, 5-Batch Analysis of Tebuconazole TGAI-[PRIVACY INFO REMOVED], DACO: 2.13.1,2.13.2,2.13.3,2.13.4 CBI
3126222	2016, Purity Profile of 5 Batches of Tebuconazole Technical-[PRIVACY INFO REMOVED], DACO: 2.13.1,2.13.2,2.13.3,2.13.4 CBI
3126223	2015, Preliminary Analysis and Enforcement Analytical Method of Tebuconazole TGAI-[PRIVACY INFO REMOVED], DACO: 2.13.1,2.13.2 CBI
3126224	2015, Preliminary Analysis and Enforcement Analytical Method of Tebuconazole TGAI-[PRIVACY INFO REMOVED], DACO: 2.13.1,2.13.2,2.13.3,2.13.4 CBI
3275276	2021, 2020-2111 Manufacturing Process [PRIVACY INFO REMOVED], DACO: 2.11,2.11.1,2.11.2,2.11.3 CBI
3275278	2019, 2020-2111 Manufacturing Process [PRIVACY INFO REMOVED], DACO: 2.11,2.11.1,2.11.2,2.11.3,2.11.4 CBI
3275279	2021, 2020-2111 5BA Study Report G19762 [PRIVACY INFO REMOVED]_02Mar2021, DACO: 2.13,2.13.1,2.13.2,2.13.3,2.13.4 CBI
3275280	2021, 2020-2111 5BA K566_AR Study Report 7C_16Aug2021, DACO: 2.13,2.13.1,2.13.2,2.13.3,2.13.4 CBI

3275281 2021, 2020-2111 5BA K593_AR Study Report 7C_14Sep2021, DACO:
2.13,2.13.1,2.13.2,2.13.3,2.13.4 CBI

3275282 2021, 2020-2111 5BA K567_AR Study Report [PRIVACY INFO REMOVED]
16Aug2021, DACO: 2.13,2.13.1,2.13.2,2.13.3,2.13.4 CBI

3275283 2021, 2020-2111 5BA K567_AR Study Report [PRIVACY INFO REMOVED]
Amendment 1_31Aug2021, DACO: 2.13,2.13.1,2.13.2,2.13.3,2.13.4 CBI

3275284 2021, 2020-2111 5BA NC-2021-008 Study Report [PRIVACY INFO
REMOVED]_27Apr2021, DACO: 2.13,2.13.1,2.13.2,2.13.3,2.13.4 CBI

3369933 2021, Manufacturing Process and Synthesis Pathway Tebuconazole Technical -
[PRIVACY INFO REMOVED], DACO: 2.11.1,2.11.2,2.11.3 CBI

© Her Majesty the Queen in Right of Canada, as represented by the Minister of Health Canada, 2022

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of Health Canada, Ottawa, Ontario K1A 0K9.